Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: Results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up

Simple item page
dc.contributor.authorWirth M.
dc.contributor.authorTyrrell C.
dc.contributor.authorDelaere K.
dc.contributor.authorSanchez-Chapado M.
dc.contributor.authorRamon J.
dc.contributor.authorWallace D.M.A.
dc.contributor.authorHetherington J.
dc.contributor.authorPina F.
dc.contributor.authorHeyns C.F.
dc.contributor.authorNavani S.
dc.contributor.authorArmstrong J.
dc.date.accessioned2011-05-15T16:17:46Z
dc.date.available2011-05-15T16:17:46Z
dc.date.issued2007
dc.description.abstractTrial 24, one of three ongoing trials in the Early Prostate Cancer programme, is evaluating the efficacy and tolerability of bicalutamide (Casodex) 150 mg following standard care (radiotherapy, radical prostatectomy or watchful waiting) in patients with early, non-metastatic prostate cancer. At 7 years' median follow-up, addition of bicalutamide significantly improved objective progression-free survival (PFS) for patients with locally advanced disease, reducing the risk of progression by 34% versus standard care alone (hazard ratio 0.66; 95% confidence interval 0.55, 0.79; P<0.001). In localized disease, a significant difference in objective PFS was not found. There was no significant difference in overall survival.
dc.description.versionArticle
dc.identifier.citationProstate Cancer and Prostatic Diseases
dc.identifier.citation10
dc.identifier.citation1
dc.identifier.issn13657852
dc.identifier.other10.1038/sj.pcan.4500916
dc.identifier.urihttp://hdl.handle.net/10019.1/14360
dc.subjectantiandrogen
dc.subjectbicalutamide
dc.subjectplacebo
dc.subjectadult
dc.subjectadvanced cancer
dc.subjectaged
dc.subjectarthralgia
dc.subjectarthritis
dc.subjectarticle
dc.subjectasthenia
dc.subjectbackache
dc.subjectcancer growth
dc.subjectcancer localization
dc.subjectcancer survival
dc.subjectclinical trial
dc.subjectconstipation
dc.subjectcontrolled clinical trial
dc.subjectcontrolled study
dc.subjectdisease free survival
dc.subjectdouble blind procedure
dc.subjectdrug efficacy
dc.subjectdrug eruption
dc.subjectdrug fatality
dc.subjectdrug tolerability
dc.subjectdrug withdrawal
dc.subjectearly cancer
dc.subjectfollow up
dc.subjectgynecomastia
dc.subjecthematuria
dc.subjecthernia
dc.subjecthot flush
dc.subjecthuman
dc.subjecthypercholesterolemia
dc.subjectimpotence
dc.subjectlibido
dc.subjectliver function test
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmastalgia
dc.subjectmetastasis potential
dc.subjectmulticenter study
dc.subjectmultimodality cancer therapy
dc.subjectoverall survival
dc.subjectpain
dc.subjectpatient care
dc.subjectpriority journal
dc.subjectprostate cancer
dc.subjectprostatectomy
dc.subjectrandomized controlled trial
dc.subjectrisk reduction
dc.subjectside effect
dc.subjectsomnolence
dc.subjecturinary tract infection
dc.subjecturine incontinence
dc.subjectweight gain
dc.subjectAnilides
dc.subjectAntineoplastic Agents
dc.subjectCarcinoma
dc.subjectChemotherapy, Adjuvant
dc.subjectCombined Modality Therapy
dc.subjectDisease-Free Survival
dc.subjectDouble-Blind Method
dc.subjectFollow-Up Studies
dc.subjectHumans
dc.subjectMale
dc.subjectNitriles
dc.subjectPlacebos
dc.subjectProstatectomy
dc.subjectProstatic Neoplasms
dc.subjectRadiotherapy
dc.subjectSurvival Analysis
dc.subjectTosyl Compounds
dc.subjectTreatment Outcome
dc.titleBicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: Results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up
dc.typeArticle
Files
Collections
Stellenbosch University - Scopus Tygerberg Hospital Publications